Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Ischemic Heart Disease

Free Subscription 23.02.2026 1 Am Heart J 1 Ann Intern Med 1 Catheter Cardiovasc Interv 2 Circ Cardiovasc Imaging 3 Circ Cardiovasc Interv 1 Circ Genom Precis Med 1 Circ Heart Fail 4 Circulation 1 Clin Cardiol 1 Eur Heart J 5 Int J Cardiol 15 J Am Coll Cardiol 4 J Cardiovasc Pharmacol 1 J Clin Invest 1 J Electrocardiol 1 J Thorac Cardiovasc Surg 8 N Engl J Med 1 PLoS One 1 Proc Natl Acad Sci U S A 1 Prog Cardiovasc Dis

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am Heart J

1. HERBERT BM, Carson JL, Bertolet M, Alexander JH, et al
   A Comprehensive Set of Per-Protocol Analyses of the Myocardial Ischemia and Transfusion (MINT) Trial.
   Am Heart J. 2026 Feb 18:107382. doi: 10.1016/j.ahj.2026.107382.
   PubMed         Abstract available
   
   

   
   Ann Intern Med

2. KELSEY MD
   In patients with CAD, clopidogrel vs. aspirin monotherapy reduces MACCE without increasing major bleeding.
   Ann Intern Med. 2026;179:JC16.
   PubMed         Abstract available
   
   

   
   Catheter Cardiovasc Interv

3. ROH KH, Kim YH, Choo EH, Lee KY, et al
   The Prognostic Impact of Multiple Adverse Events on Long-Term Mortality Following Acute Myocardial Infarction.
   Catheter Cardiovasc Interv. 2026 Feb 18. doi: 10.1002/ccd.70521.
   PubMed         Abstract available
   
   

   
   Circ Cardiovasc Imaging

4. QI J, Yue X, Hu M, Cui J, et al
   Synthetic Contrast-Free LGE via Diffusion-Based Framework in Acute MI for Image Quality and Quantitative Scar Analysis.
   Circ Cardiovasc Imaging. 2026;19:e018967.
   PubMed         Abstract available
   
   
5. TOPRICEANU CC, Webber M, Shiwani H, Chan F, et al
   Higher Life-Course Blood Pressure Associates With Reduced Myocardial Perfusion in Older Age: Insights From MyoFit46.
   Circ Cardiovasc Imaging. 2025 Nov 8:e019105. doi: 10.1161/CIRCIMAGING.125.019105
   PubMed         Abstract available
   
   

   
   Circ Cardiovasc Interv

6. RYMER JA, Li S, Chiswell K, Smilowitz NR, et al
   Impact of In-Hospital STEMI on Reperfusion Times and Clinical Outcomes.
   Circ Cardiovasc Interv. 2026;19:e015547.
   PubMed         Abstract available
   
   
7. MANSOOR H, Young R, Kaltenbach LA, Wojdyla DM, et al
   Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry.
   Circ Cardiovasc Interv. 2026;19:e015600.
   PubMed         Abstract available
   
   
8. LOUCA A, Petursson P, Sundstrom J, Hagstrom H, et al
   PCI Versus Conservative Management Before TAVR in Patients With Significant Coronary Artery Disease: A Nationwide Instrumental Variable Analysis.
   Circ Cardiovasc Interv. 2026 Feb 20:e016337.
   PubMed         Abstract available
   
   

   
   Circ Genom Precis Med

9. TSAO NL, Abramowitz SA, Shakt GE, Judy R, et al
   Angiographic Burden of Coronary Atherosclerosis Partially Mediates the Association Between ASCVD Risk Factors and Outcomes.
   Circ Genom Precis Med. 2026 Feb 20:e005266. doi: 10.1161/CIRCGEN.125.005266.
   PubMed         Abstract available
   
   

   
   Circ Heart Fail

10. MEHTA C, Has P, Mehta A, Vargas I, et al
    Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock.
    Circ Heart Fail. 2026 Feb 19:e013814. doi: 10.1161/CIRCHEARTFAILURE.125.013814.
    PubMed         Abstract available
    
    

    
    Circulation

11. BOYER TM, Barrett RB, Xiong C, Bu F, et al
    Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women.
    Circulation. 2026;153:480-492.
    PubMed         Abstract available
    
    
12. ROSEN SE
    Redefining Cardiovascular Medicine: The Journey From "Does Sex Matter?" to "How Does Sex Matter?".
    Circulation. 2026;153:534-535.
    PubMed        
    
    
13. GRAGNANO F, Giacoppo D, Choi KH, Kimura T, et al
    Clopidogrel Versus Aspirin Monotherapy in Coronary Artery Disease: A Sex-Stratified Individual Patient Data Meta-Analysis of Randomized Trials.
    Circulation. 2026;153:543-546.
    PubMed        
    
    
14. CARNETHON MR, Post WS, Hill JA, Al-Khatib SM, et al
    Go(ing) Red for Women and Fulfilling Our Commitment to Sex-Based Reporting of Cardiovascular Disease.
    Circulation. 2026;153:467-468.
    PubMed        
    
    

    
    Clin Cardiol

15. BOND P, Smit DL, Verdegaal T, de Ronde W, et al
    Preventing Atherosclerotic Cardiovascular Disease in Young Male Androgen Abusers.
    Clin Cardiol. 2026;49:e70257.
    PubMed         Abstract available
    
    

    
    Eur Heart J

16. ZARAGOZA C
    When RNAs come full circle: new regulators of healing after myocardial infarction.
    Eur Heart J. 2026 Feb 18:ehag038. doi: 10.1093.
    PubMed        
    
    

    
    Int J Cardiol

17. JIN S, Liu W, Chen X, Guo W, et al
    Caveolin-3 serves as a therapeutic target for myocardial ischemia-reperfusion injury in cardiac surgery patients.
    Int J Cardiol. 2026;449:134179.
    PubMed         Abstract available
    
    
18. FEZZI S, Zhu Y, Bargary N, Ding D, et al
    Predicting functional results of percutaneous coronary intervention using machine learning modelling.
    Int J Cardiol. 2026;449:134183.
    PubMed         Abstract available
    
    
19. LOU Q, Bai R, Li L, Lu B, et al
    Targeting ADAMTS4 aggravates myocardial ischemia-reperfusion injury by impairing endothelial integrity and accelerating leukocyte infiltration.
    Int J Cardiol. 2026;449:134195.
    PubMed         Abstract available
    
    
20. LECHNER I, Reindl M, Metzler B, Reinstadler SJ, et al
    PCSK9 and residual risk after ST-elevation myocardial infarction.
    Int J Cardiol. 2026;450:134231.
    PubMed        
    
    
21. LI S, Huo H, Zheng Y, Liu S, et al
    Radiomics with native T1 mapping for contrast-free detection of acute and chronic myocardial infarction: A multicenter study.
    Int J Cardiol. 2026 Feb 17:134222. doi: 10.1016/j.ijcard.2026.134222.
    PubMed         Abstract available
    
    

    
    J Am Coll Cardiol

22. KRUMHOLZ HM
    Women's Cardiovascular Health: From Inclusion to Design.
    J Am Coll Cardiol. 2026;87:683-684.
    PubMed        
    
    
23. YONG CM, Spatz ES, Hayes SN
    Sex Matters: Optimizing Cardiovascular Education and Training to Improve Women's (and Men's) Heart Health.
    J Am Coll Cardiol. 2026;87:742-745.
    PubMed        
    
    
24. HONIGBERG MC
    Rethinking Cholesterol Management in Women: From Short-Term Risk Estimation to Lifecourse Cardiovascular Health.
    J Am Coll Cardiol. 2026;87:746-749.
    PubMed        
    
    
25. WARRAICH H
    Tip of the Spear: The Cardiovascular Profession in the Age of AI.
    J Am Coll Cardiol. 2026 Feb 18:S0735-1097(26)00292.
    PubMed        
    
    
26. PAREEK M, Johansen ND, Modin D, Pardo-Seco J, et al
    High-Dose Influenza Vaccination in Atherosclerotic Cardiovascular Disease: A Multinational Pooled Analysis of DANFLU-2 and GALFLU (FLUNITY-HD).
    J Am Coll Cardiol. 2026 Feb 9:S0735-1097(25)10661.
    PubMed        
    
    
27. DOI T, Afzal S, Nordestgaard BG
    Risk of Atherosclerotic Cardiovascular Disease in Familial Remnant Hyperlipidemia (Dysbetalipoproteinemia) and Familial Hypercholesterolemia.
    J Am Coll Cardiol. 2026 Feb 6:S0735-1097(26)00135.
    PubMed        
    
    
28. KRUMHOLZ HM
    When Care Becomes Autonomous: AI and the Future of Cardiovascular Medicine.
    J Am Coll Cardiol. 2026 Feb 18:S0735-1097(26)00300.
    PubMed        
    
    
29. ZHANG S, Wang Y, Wei J, Benmarhnia T, et al
    Impact of Long-Term Cumulative Exposure to Wildfire Smoke PM(2.5) on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study.
    J Am Coll Cardiol. 2026 Feb 18:S0735-1097(25)10660.
    PubMed         Abstract available
    
    
30. NEIRA M
    PM(2.5) Spikes and Cardiovascular Mortality: Policy Priorities for Air Quality Alerts.
    J Am Coll Cardiol. 2026 Feb 6:S0735-1097(25)10410.
    PubMed        
    
    
31. MANGNER N, Beske RP, Hassager C, Jensen LO, et al
    Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.
    J Am Coll Cardiol. 2026;87:704-719.
    PubMed         Abstract available
    
    
32. GLAESER J, Lopez-Ayala P, Kellner C, Boeddinghaus J, et al
    Comparison of the European Society of Cardiology 0/1-Hour and High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome 0/2-or-0/3-Hour Algorithms for Rapid Myocardial Infarction Diagnosis: A Prospective Multicente
    J Am Coll Cardiol. 2026 Feb 10:S0735-1097(25)10588.
    PubMed         Abstract available
    
    
33. YANG J, Yin P, Li M, Gao Y, et al
    Long-Term Cardiovascular and Noncardiovascular Mortality After Acute Coronary Syndrome: A Nationwide Competing-Risks Analysis of 1.56 Million Patients.
    J Am Coll Cardiol. 2026 Feb 6:S0735-1097(25)10597.
    PubMed         Abstract available
    
    
34. YANG Y, Deng J, Zhou P, Li P, et al
    Short-Term PM(2.5) Exposure and Cardiovascular Mortality: A Global Exposure-Response Analysis to Inform Alert Thresholds.
    J Am Coll Cardiol. 2026 Feb 6:S0735-1097(25)10589.
    PubMed         Abstract available
    
    
35. ABOU-KARAM R, Kim MS, Jemma Cho SM, Bitar F, et al
    Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials.
    J Am Coll Cardiol. 2026 Feb 6:S0735-1097(25)10563.
    PubMed         Abstract available
    
    
36. YANG C, Bai L, Wu S
    Nonlinear Association Evidence and Optimal Alert Thresholds for Global Short-Term PM(2.5) Exposure and Cardiovascular Mortality Risk.
    J Am Coll Cardiol. 2026 Jan 22:S0735-1097(25)10475.
    PubMed        
    
    

    
    J Cardiovasc Pharmacol

37. BIONDI-ZOCCAI G, Frati G, Booz GW
    Closing the translational gap in cardiovascular artificial intelligence: from drug discovery to evidence synthesis.
    J Cardiovasc Pharmacol. 2026 Feb 18. doi: 10.1097/FJC.0000000000001808.
    PubMed        
    
    
38. GIORDANO S, Morello A, Biondi-Zoccai G, Corcione N, et al
    When Phenotyping Is the Intervention: Personlized Treatment of Diffuse Coronary Artery Disease.
    J Cardiovasc Pharmacol. 2026 Feb 18. doi: 10.1097/FJC.0000000000001809.
    PubMed        
    
    
39. GIBSON CM, Escano AK, Hobe KD, Brody ER, et al
    Safety and effectiveness of somatostatin and analogues on chest tube output after coronary artery bypass grafting: A scoping review.
    J Cardiovasc Pharmacol. 2026 Feb 19. doi: 10.1097/FJC.0000000000001810.
    PubMed         Abstract available
    
    
40. WANG G, Luo Y, Song S, Li X, et al
    Role of the Gut Microbiome in Modulating Interactions Between beta-Lactam Antibiotics and Statins in Coronary Heart Disease.
    J Cardiovasc Pharmacol. 2026 Feb 17. doi: 10.1097/FJC.0000000000001805.
    PubMed         Abstract available
    
    

    
    J Clin Invest

41. KAHLES F, Birkenfeld AL, Marx N
    GLP-1 and the cardiovascular system.
    J Clin Invest. 2026;136:e194748.
    PubMed         Abstract available
    
    

    
    J Electrocardiol

42. NI H, Wan X, Shi T, Gao Z, et al
    A new and modified northern occlusion myocardial infarction pattern.
    J Electrocardiol. 2026;95:154212.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

43. HASAN I, Bessette LG, Jacquemyn X, Wang Y, et al
    Association of GLP-1 Inhibitors with Cardiovascular Outcomes in Patients Undergoing Coronary Artery Bypass Surgery.
    J Thorac Cardiovasc Surg. 2026 Feb 17:S0022-5223(26)00114.
    PubMed         Abstract available
    
    

    
    N Engl J Med

44. RAHHAL A, Al Hijji M, Arabi AR
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:820.
    PubMed        
    
    
45. CHI KY, Mangalesh S, Nanna MG
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:820-821.
    PubMed        
    
    
46. LLOP D, Turu M, Llop C
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:821.
    PubMed        
    
    
47. GAMARDELLA M, Ciconte G, Pappone C
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:822.
    PubMed        
    
    
48. ZIEMINSKI JJ, Bell MR
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:822-823.
    PubMed        
    
    
49. IBANEZ B, Latini R, Rossello X
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2026;394:823-824.
    PubMed        
    
    
50. MUNKHAUGEN J, Atar D, Prescott E
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2026;394:824-825.
    PubMed        
    
    
51. CEREDA A, Stracqualursi M, Lucreziotti S
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:821-822.
    PubMed        
    
    

    
    PLoS One

52. FU W, Lin J, Lin W, Zeng K, et al
    FNDC5/Irisin-dependent renoprotection of resistance training in myocardial infarction-induced Type 2 cardiorenal syndrome.
    PLoS One. 2026;21:e0342468.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

53. XU Y, Chen Y, Wang Y, Yang Z, et al
    Artificially constructed collagen-targeting receptors on mesenchymal stromal cells promote anoikis resistance and tissue repair.
    Proc Natl Acad Sci U S A. 2026;123:e2525881123.
    PubMed         Abstract available
    
    

    
    Prog Cardiovasc Dis

54. PEI H, He L, Wang S, Mo C, et al
    Association between gout and cardiovascular disease: A register-based cohort study.
    Prog Cardiovasc Dis. 2026 Feb 16:S0033-0620(26)00008.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum